Selventa's David de Graaf Appointed as a Scientific Advisory Board Member for Massachusetts Institute of Technology (MIT)'s Center for Cancer Systems Biology
Published: Sep 12, 2011
“Currently, there is a great need for industry and academic research to join together to better understand complex diseases through advancement of tools and analytical methods,” said Doug Lauffenburger, Ph.D., Principal Investigator of the CCSB, Ford Professor of Bioengineering and Head of the MIT Department of Biological Engineering, and member of the Koch Institute for Integrative Cancer Research. “Assembly of thought leaders who can provide critical feedback on the direction of these initiatives will ultimately benefit human health. David embodies the depth of scientific understanding that we seek and is well recognized in the industry for successfully integrating systems biology into R&D pipelines.”
MIT’s ‘Tumor Cell Networks Center’ is one of the 10 CCSB formed under the Integrative Cancer Biology Program by the National Cancer Institute. CCSB focuses on developing and implementing computational models to comprehensively analyze cancer as a complex biological system. The goal is to the foster the innovation of technology as well as advancement in computational and mathematical modeling tools to unravel the complexities of cancer through a unique multidisciplinary team of outstanding researchers.
“I am honored to be elected as a Scientific Advisory Board member,” said David de Graaf, Ph.D., President and CEO of Selventa. “I feel grateful to be in a position where I can help inspiring researchers improve the lives of patients through scientific advances. Understanding the mechanisms of complex diseases and finding the right treatments for the right patients would make all the hard work worth the while.”
Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, software and strategic partnerships. The company analyzes molecular patient data, accelerates the development process and clarifies therapeutics and diagnostics decisions. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety. For more information, visit www.selventa.com.
About the Koch Institute
The David H. Koch Institute for Integrative Cancer Research (pronounced "coke") is a cancer research center affiliated with the Massachusetts Institute of Technology (MIT) located in Cambridge, Massachusetts. The Institute is one of six National Cancer Institute-designated basic research centers in the US. The Koch Institute (KI) was launched in October of 2007 and is physical home to ~25 MIT faculty members from both the Schools of Engineering and Science and convenes over 1,000 researchers from across the MIT campus. KI fosters and funds interdisciplinary collaborations in five key research areas: nanotherapeutics, detection and monitoring, metastasis, mapping drug sensitivity & resistance pathways, and cancer immunology. For more information, visit http://ki.mit.edu/.
For more information, please contact:
Diane H. Song, Ph.D., 617-547-5421 x235
Paul Kidwell, 617-296-3854